BioAffinity Shares Soar 54% on CyPath® Lung Clinical Wins and Board Upgrades

Introduction

BIOAFFINITY TECHNOLOGIES INC (NASDAQ: BIAF) is a biotechnology company headquartered in San Antonio, Texas, focused on noninvasive, early-stage lung cancer diagnostics. Its lead product, CyPath® Lung, is a laboratory-developed test offered through Precision Pathology Laboratory Services. By applying flow cytometry to sputum samples, CyPath® Lung distinguishes malignant from benign cell populations, addressing limitations of low-dose computed tomography (LDCT) screening.

Corporate Structure

As of September 2023, bioAffinity employs between 11 and 50 people. The management team combines scientific, clinical, and financial expertise:

• Maria Zannes, President & Chief Executive Officer, has over 30 years of executive-level experience across diagnostics, therapeutics, and energy industries.
• J. Michael Edwards, MBA, CPA, rejoined as Chief Financial Officer in 2023 to oversee the ongoing commercialization of CyPath® Lung; he has more than 30 years in financial management and strategy.
• William Bauta, PhD, Chief Science Officer, is a medicinal chemist with more than 25 years in drug discovery and development.
• Gordon Downie, MD, PhD, Chief Medical Officer, has three decades of experience in pulmonary medicine and clinical research.
• Xavier T. Reveles, MS, CG(ASCP)GM, Chief Operating Officer, has over 25 years in clinical genetics and CLIA lab management.

Lung cancer diagnostics by Robina Weermeijer

Developments and News

• In August 2023, U.S. Medicine magazine's pulmonary issue featured a case study emphasizing CyPath® Lung’s economic impact for veterans' health programs.
• A case study highlighted on LinkedIn described CyPath® Lung identifying malignancy in a 66-year-old patient with ground-glass pulmonary nodules, demonstrating 92% sensitivity and 87% specificity for nodules smaller than 20 mm.
• In mid-2023, bioAffinity appointed Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its board of directors, enhancing financial governance and clinical expertise.
• On September 15, 2023, BIAF shares traded at USD 0.4152, up 53.78% intraday on NASDAQ, with a volume of 43,365,106 shares.

Financial and Strategic Analysis

At USD 0.4152 per share, bioAffinity’s market capitalization classifies it as a small-cap issuer. The 53.78% price increase on September 15 reflects investor interest in clinical validation milestones and board enhancements. Strategically, bioAffinity’s licensing arrangement with Precision Pathology Laboratory Services for CyPath® Lung supports product commercialization without the capital intensity of building an in-house testing infrastructure. Ongoing flow cytometry research and an early-stage therapeutics pipeline under OncoSelect® Therapeutics provide additional avenues for long-term growth.

Market Position and Industry Context

Lung cancer screening protocols primarily rely on LDCT, which can yield false positives and lead to invasive follow-up procedures. CyPath® Lung targets the sub-20 mm nodule segment, where the positive predictive value of imaging is limited. By offering noninvasive adjunct testing with high sensitivity and specificity, bioAffinity aims to position itself within the molecular diagnostics segment of the oncology market. The company competes with emerging liquid-biopsy developers and traditional imaging providers, seeking to establish CyPath® Lung as a standard follow-up to indeterminate LDCT findings.

TL;DR

On September 15, 2023, BIAF shares increased by 53.78% to USD 0.4152 on heavy trading (43.4 million shares) following the publication of veteran-focused economic data in U.S. Medicine and a LinkedIn case demonstrating CyPath® Lung’s performance in ground-glass nodules. The board additions of Roberto Rios and Dr. John Oppenheimer in mid-2023 strengthened financial and clinical governance. The company’s licensing model with Precision Pathology Laboratory Services supports near-term commercialization, while ongoing flow cytometry research and OncoSelect® Therapeutics efforts outline future development paths.